(Bloomberg) — An accelerated approval program for U.S. drugs that’s been around for almost three decades is under fire for the criteria used by regulators to decide which therapies should be greenlighted, and for letting ineffective treatments linger on the market. The Food and Drug Administration’s accelerated process has been hailed for quickly addressing unmet […]
>> CLICK HERE << Get A FREE Copy Of My Special Report
“Can Your Retirement Survive” Today!
We Even Pay For Shipping & Handling!
|Click Here To Request Your FREE IRS Loophole Guide|
This post contains affiliate links. If you use these links to buy something we may earn a commission. Thanks.”